{"id":42262,"date":"2025-09-25T14:45:27","date_gmt":"2025-09-25T06:45:27","guid":{"rendered":"https:\/\/flcube.com\/?p=42262"},"modified":"2025-09-25T14:45:28","modified_gmt":"2025-09-25T06:45:28","slug":"eisai-and-biogen-secure-australian-tga-approval-for-lecanemab-in-early-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42262","title":{"rendered":"Eisai and Biogen Secure Australian TGA Approval for Lecanemab in Early Alzheimer\u2019s Disease"},"content":{"rendered":"\n<p><strong>Eisai (<a href=\"https:\/\/www.google.com\/finance\/quote\/4523:TYO\">TYO: 4523<\/a>)<\/strong> and <strong>Biogen Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/BIIB:NASDAQ\">NASDAQ: BIIB<\/a>)<\/strong> announced today that the Australian Therapeutic Goods Administration (TGA) has granted approval for <strong>Lecanemab<\/strong> (LEQEMBI\u00ae), a humanized anti\u2011soluble aggregated amyloid\u2011\u03b2 (A\u03b2) monoclonal antibody, for the treatment of mild cognitive impairment (MCI) or mild dementia attributable to Alzheimer\u2019s disease (AD). The indication is limited to adults who are either <strong>ApoE\u03b54 non\u2011carriers<\/strong> or <strong>heterozygous carriers<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-what-the-approval-means\">What the Approval Means<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Geographic Expansion<\/strong> \u2013 Lecanemab is now the first anti\u2011A\u03b2 monoclonal antibody approved in Australia, adding to its existing authorizations in the United States, Japan, China, and the European Union.<\/li>\n\n\n\n<li><strong>Clinical Impact<\/strong> \u2013 By targeting and continuously clearing neurotoxic protofibrils and A\u03b2 plaques, Lecanemab is designed to slow disease progression in patients with early AD.<\/li>\n\n\n\n<li><strong>Commercial Strategy<\/strong> \u2013 Eisai remains the lead developer and global regulator for Lecanemab, while Eisai and Biogen will co\u2011commercialize and co\u2011promote the product worldwide, with Eisai holding final decision\u2011making authority. In the EU (excluding the Nordic countries), the two companies will co\u2011promote the drug, with Eisai serving as the Marketing Authorization Holder.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-partnership-dynamics\">Partnership Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Joint Development &amp; Regulation<\/strong> \u2013 Eisai\u2019s global development pipeline is complemented by Biogen\u2019s robust commercial network, ensuring rapid market access and patient reach.<\/li>\n\n\n\n<li><strong>Strategic Decision Framework<\/strong> \u2013 The co\u2011promotion agreement balances shared marketing responsibilities with Eisai\u2019s final decision authority, streamlining regulatory and commercial execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Eisai (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) announced today that the Australian Therapeutic Goods&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42263,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[351,993,15,1151],"class_list":["post-42262","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-biogen","tag-nasdaq-biib","tag-product-approvals","tag-tyo-4523"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eisai and Biogen Secure Australian TGA Approval for Lecanemab in Early Alzheimer\u2019s Disease - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eisai (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) announced today that the Australian Therapeutic Goods Administration (TGA) has granted approval for Lecanemab (LEQEMBI\u00ae), a humanized anti\u2011soluble aggregated amyloid\u2011\u03b2 (A\u03b2) monoclonal antibody, for the treatment of mild cognitive impairment (MCI) or mild dementia attributable to Alzheimer\u2019s disease (AD). The indication is limited to adults who are either ApoE\u03b54 non\u2011carriers or heterozygous carriers.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42262\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai and Biogen Secure Australian TGA Approval for Lecanemab in Early Alzheimer\u2019s Disease\" \/>\n<meta property=\"og:description\" content=\"Eisai (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) announced today that the Australian Therapeutic Goods Administration (TGA) has granted approval for Lecanemab (LEQEMBI\u00ae), a humanized anti\u2011soluble aggregated amyloid\u2011\u03b2 (A\u03b2) monoclonal antibody, for the treatment of mild cognitive impairment (MCI) or mild dementia attributable to Alzheimer\u2019s disease (AD). The indication is limited to adults who are either ApoE\u03b54 non\u2011carriers or heterozygous carriers.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42262\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-25T06:45:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-25T06:45:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2510.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42262#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42262\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eisai and Biogen Secure Australian TGA Approval for Lecanemab in Early Alzheimer\u2019s Disease\",\"datePublished\":\"2025-09-25T06:45:27+00:00\",\"dateModified\":\"2025-09-25T06:45:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42262\"},\"wordCount\":241,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42262#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2510.webp\",\"keywords\":[\"Biogen\",\"NASDAQ: BIIB\",\"Product approvals\",\"TYO: 4523\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42262#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42262\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42262\",\"name\":\"Eisai and Biogen Secure Australian TGA Approval for Lecanemab in Early Alzheimer\u2019s Disease - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42262#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42262#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2510.webp\",\"datePublished\":\"2025-09-25T06:45:27+00:00\",\"dateModified\":\"2025-09-25T06:45:28+00:00\",\"description\":\"Eisai (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) announced today that the Australian Therapeutic Goods Administration (TGA) has granted approval for Lecanemab (LEQEMBI\u00ae), a humanized anti\u2011soluble aggregated amyloid\u2011\u03b2 (A\u03b2) monoclonal antibody, for the treatment of mild cognitive impairment (MCI) or mild dementia attributable to Alzheimer\u2019s disease (AD). The indication is limited to adults who are either ApoE\u03b54 non\u2011carriers or heterozygous carriers.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42262#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42262\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42262#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2510.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2510.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eisai and Biogen Secure Australian TGA Approval for Lecanemab in Early Alzheimer\u2019s Disease\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42262#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eisai and Biogen Secure Australian TGA Approval for Lecanemab in Early Alzheimer\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eisai and Biogen Secure Australian TGA Approval for Lecanemab in Early Alzheimer\u2019s Disease - Insight, China&#039;s Pharmaceutical Industry","description":"Eisai (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) announced today that the Australian Therapeutic Goods Administration (TGA) has granted approval for Lecanemab (LEQEMBI\u00ae), a humanized anti\u2011soluble aggregated amyloid\u2011\u03b2 (A\u03b2) monoclonal antibody, for the treatment of mild cognitive impairment (MCI) or mild dementia attributable to Alzheimer\u2019s disease (AD). The indication is limited to adults who are either ApoE\u03b54 non\u2011carriers or heterozygous carriers.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42262","og_locale":"en_US","og_type":"article","og_title":"Eisai and Biogen Secure Australian TGA Approval for Lecanemab in Early Alzheimer\u2019s Disease","og_description":"Eisai (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) announced today that the Australian Therapeutic Goods Administration (TGA) has granted approval for Lecanemab (LEQEMBI\u00ae), a humanized anti\u2011soluble aggregated amyloid\u2011\u03b2 (A\u03b2) monoclonal antibody, for the treatment of mild cognitive impairment (MCI) or mild dementia attributable to Alzheimer\u2019s disease (AD). The indication is limited to adults who are either ApoE\u03b54 non\u2011carriers or heterozygous carriers.","og_url":"https:\/\/flcube.com\/?p=42262","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-25T06:45:27+00:00","article_modified_time":"2025-09-25T06:45:28+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2510.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42262#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42262"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eisai and Biogen Secure Australian TGA Approval for Lecanemab in Early Alzheimer\u2019s Disease","datePublished":"2025-09-25T06:45:27+00:00","dateModified":"2025-09-25T06:45:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42262"},"wordCount":241,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42262#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2510.webp","keywords":["Biogen","NASDAQ: BIIB","Product approvals","TYO: 4523"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42262#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42262","url":"https:\/\/flcube.com\/?p=42262","name":"Eisai and Biogen Secure Australian TGA Approval for Lecanemab in Early Alzheimer\u2019s Disease - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42262#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42262#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2510.webp","datePublished":"2025-09-25T06:45:27+00:00","dateModified":"2025-09-25T06:45:28+00:00","description":"Eisai (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) announced today that the Australian Therapeutic Goods Administration (TGA) has granted approval for Lecanemab (LEQEMBI\u00ae), a humanized anti\u2011soluble aggregated amyloid\u2011\u03b2 (A\u03b2) monoclonal antibody, for the treatment of mild cognitive impairment (MCI) or mild dementia attributable to Alzheimer\u2019s disease (AD). The indication is limited to adults who are either ApoE\u03b54 non\u2011carriers or heterozygous carriers.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42262#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42262"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42262#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2510.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2510.webp","width":1080,"height":608,"caption":"Eisai and Biogen Secure Australian TGA Approval for Lecanemab in Early Alzheimer\u2019s Disease"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42262#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eisai and Biogen Secure Australian TGA Approval for Lecanemab in Early Alzheimer\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2510.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42262","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42262"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42262\/revisions"}],"predecessor-version":[{"id":42264,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42262\/revisions\/42264"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42263"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}